0000939767-18-000123.txt : 20180703
0000939767-18-000123.hdr.sgml : 20180703
20180703210751
ACCESSION NUMBER: 0000939767-18-000123
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180702
FILED AS OF DATE: 20180703
DATE AS OF CHANGE: 20180703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwab Gisela
CENTRAL INDEX KEY: 0001213140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 18939326
MAIL ADDRESS:
STREET 1: 6701 KAISER DRIVE
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER NAME:
FORMER CONFORMED NAME: SCHWAB GISELA MD
DATE OF NAME CHANGE: 20030107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1228
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_153066645574683.xml
FORM 4
X0306
4
2018-07-02
0
0000939767
EXELIXIS, INC.
EXEL
0001213140
Schwab Gisela
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
Pres Prod Dev & Med Aff & CMO
Common Stock
2018-07-02
4
M
0
22500
5.50
A
300788
D
Common Stock
2018-07-02
4
S
0
22500
21.20
D
278288
D
Common Stock
14505
I
By 401(k)
Option (right to buy)
5.5
2018-07-02
4
M
0
22500
0
D
2012-09-28
2018-09-27
Common Stock
22500.0
45000
D
Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.10 to $21.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 2, 2018.
The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2018-07-03